Introduction
Our objective in this article is to start an intensive dialogue between academic researchers and risk assessment agencies, on what are the determinants of reliable chronic toxicity test for a risk assessment of chemicals ('risk assessment'). Two opposing paradigms control toxicology -'academic' and 'regulatory'. We define the former as investigations by researchers largely at universities and medical institutions. The latter however developed mostly in the nascent organic chemistry industry (especially synthetic pharmaceuticals), creating the toxicity test methods (Borzelleca, 1994) on which risk assessment relies on today, as we will demonstrate. We concentrate on the chronic exposure test, as it largely determines the regulation of agents in commerce, representing population-wide exposures. Risk assessment's methods were unified in a globallyadopted four-step paradigm by the US National Research Council's 'Red Book' (USNRC, 1983) .
Other than an occasional regulator's generation of exposure data, a large information asymmetry exists in risk assessment. Companies investigate the physio-chemical character of molecules for marketable properties, including interactions with biologic systems. If a molecule appears worth commercialising, these data inform the necessary toxicity investigations (including on the agent's behaviour in organisms -adsorption to excretion), such as the dose level for in vitro and then in vivo acute toxicity tests. Such test results inform the dose levels for a sub-chronic exposure test, whose potency results finally informs the doses for the chronic toxicity test (Klaassen et al., 2013) . This 'dose ranging' process is needed for a risk assessment, which aims to find a safe dose under all anticipated exposure scenarios.
The manufacturer performs these dose-ranging toxicity tests because the molecule promises profit if found safe enough to use. studies with academia's studies (Bekelman et al., 2003; Diels et al., 2011; Domingo and Bordonaba, 2011; Fagin and Lavelle, 2002; Hayes, 2004; Lesser et al., 2007; Swaen and Meijers, 1988; vom Saal and Hughes, 2005) . These clearly show that industry studies find little or no toxicity, while publicly funded studies of the same chemical realistically yield mixed results, including many findings of low dose toxicity.
Agents including arsenic, lead, mercury, ozone, particulate matter and dioxin-like compounds have had their 'safe' dose repeatedly lowered over the decades until it is generally conceded that they may have no safe exposure level, but this has not occurred for any strictly commercial agents. Rather, regulatory agencies while respecting the findings of academic science as 'hypothesis-raising', seem to require the more unrealistic standardized data resulting from dose-ranging.
Yet one may pick any well-known agent (so it has a large enough published toxicity literature) and see published findings of chronic mammalian toxicity at doses lower than the LOAEL claimed in its risk assessments. We list a few dozen examples in Tables 1 and 2 (some are even more potent than some of the LOAELs in the IRIS database). Parenthetic to our purpose, we note that ecological risk assessment seldom performs any chronic exposure test at all. However fixing the mammalian chronic assay's insensitivity would benefit all species.
What makes TG-GLP tests so insensitive?
Any study has shortcomings, but why do TG-GLP methods so regularly fail to find toxicity at the levels that organisms are typically exposed to, when other test methods do? Here are the main insensitivities of TG chronic test methods:
(1) A TG test sacrifices the animals at the end of dosing, at human equivalent of circa 60 years old, before most chronic disease manifests -e.g. 77% of malignant tumours are diagnosed after age 55 in the USA (ACS, 2013). (2) Not enough tests of developmental toxicity are done, despite the complex vulnerability of development, which drives much disease, even in adulthood (Hanson and Gluckman, 2011). (3) Data from concurrent negative controls in a TG-GLP experiment are allowed (OECD, 2012b) to be diluted, even overridden, by historical control data drawn from experiments carried out in a wide range of different conditions (accordingly, they are used in many risk assessments). Some of the variables not well controlled when using the often secret historical controls include strain and origin of animals, laboratory in which the experiment was carried out, dietary factors; environmental contaminants in air, bedding, food, and water; differences in diagnostic criteria among pathologists, and the year in which the experiment was performed; all which can produce very different results (Haseman, 1984; Hardisty, 1985) . (4) Positive controls (when feasible) limit false negative results (Myers et al., 2009 ), but are never mentioned in the TGs or in guidance. (5) Toxicity is almost always detected with the light microscope and a few gross biochemistry measures, rather than also employing academia's advanced imaging and biochemistry methods (Koshland Jr., 1998). (6) As just described, the TG's high dose levels tend to elicit a quasi-poisoning syndrome that is irrelevant to the effect of the doses encountered in the biosphere, which remain untested by TGs. Table 2 In-vivo refutations of most protective TTC's assumed NOAEL, 150 μg/kg bw d-. For many years industry has promoted the Threshold of Toxicologic Concern (TTC) as a substitute for chronic toxicity testing. A TTC is a claimed safe dose for effect categories of agents (genotoxic, endocrine-disrupting, etc. (the latter's appropriateness for the TTC is still being debated). A TTC is set below the LOAELs of up to a few hundred existing toxicity results; but with the usual preference for TG-GLP-generated results. Consequently, it is just as easy to find examples of more potent toxicity than a TTC as it is for those in Table 1 . Here even the most protective of the TTCs, for Cramer Class III agents: 1.5 μg/kg d-is shown to not be protective. Many of our examples dose by feed/gavage, so the elicited toxicity is after first pass metabolism and excretion. Our example doses are mostly LOAELs while the TTC uses mostly NOAELs, so our refutations are stronger yet.
We include examples of natural hormones to emphasise how potent hormones can be. Finally we assume the standard 100-fold uncertainty factors went into this TTC, for a putative 'universal' NOAEL of 150 μg/kg d-.
